Equities researchers at Jefferies Financial Group began coverage on shares of Kyowa Kirin (OTCMKTS:KYKOF) in a note issued to investors on Monday, The Fly reports. The firm set a “buy” rating on the stock.
Kyowa Kirin stock opened at $21.65 on Monday.
Kyowa Kirin Company Profile
Kyowa Kirin Co, Ltd., specialty pharmaceutical company, manufactures and markets pharmaceuticals focused on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; GRAN, a human colony-stimulating factor; and G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia.
See Also: What are the components of an earnings report?
Receive News & Ratings for Kyowa Kirin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kyowa Kirin and related companies with MarketBeat.com's FREE daily email newsletter.